Medpace Forecasts 24% Revenue Growth, Trades at 27.6 Forward P/E
Medpace shares rose 1.69% to $478.54, outperforming the S&P 500’s 0.83% gain after a 13.18% year-to-date decline versus a 3.46% sector loss. Analysts project Q1 EPS of $3.74 (+1.9% yoy) on $694.2 million revenue (+24.3%), with full-year EPS of $17.04 (+11.5%) on $2.81 billion (+11.2%).
1. Stock Performance
Medpace closed at $478.54 on March 9, rising 1.69% in the session and outpacing the S&P 500’s 0.83% gain, the Dow’s 0.5% and Nasdaq’s 1.38%. Prior to this rally, shares had lost 13.18% year-to-date, underperforming the Medical Services sector’s 3.46% decline and the S&P 500’s 2.65%.
2. Q1 Earnings Forecast
Analysts anticipate first-quarter earnings per share of $3.74, reflecting year-over-year growth of 1.91%, on revenue of $694.24 million, up 24.29% from the prior year. This outlook incorporates a 2.49% upward revision in EPS estimates over the past month and supports a consensus rank of 3 (Hold).
3. Full-Year Outlook and Valuation
For the full fiscal year, consensus estimates call for EPS of $17.04 (+11.52%) and revenue of $2.81 billion (+11.17%). Shares trade at a forward P/E of 27.61 and a PEG ratio of 2.26 versus industry averages of 15.81 and 1.62, while the Medical Services industry sits in the bottom 45% of sectors by rank.